Results 21 to 30 of about 17,718 (201)

Efficacy, Safety and Immunogenicity of Sun’s Ranibizumab Biosimilar in Neovascular Age-Related Macular Degeneration: A Phase 3, Double-Blind Comparative Study

Ophthalmology and Therapy
Introduction The study aimed to evaluate comparability in terms of efficacy, safety and immunogenicity of Sun’s ranibizumab biosimilar with reference ranibizumab in patients with neovascular age-related macular degeneration (nAMD).
Asim K. Ghosh, Usha S. Nikumbh, Chaitanya K. Shukla, Rohit S. Laul, Abhishek Dixit, Santosh K. Mahapatra, Sameera Nayak, Urmil M. Shah, Sandeep Parwal, Narendran Venkatapathy, Natasha Radhakrishnan, Anup Kelgaonkar, Sandeep Saxena, Divyansh Mishra, Vivek Pravin Dave, Perwez Khan, Manojkumar R. Saswade, Malli S. Shantilal, Kim Ramasamy, Smitha Sreekanta, Mandodari Rajurkar, Maulik Doshi, Sapan Behera, Piyush Patel, Shilpi Dhawan, Lalit Lakhwani   +25 more
doaj   +1 more source

DNA Nanoflower LYTACs Enable Efficient VEGF Degradation and Verteporfin Loading for Combined Therapy of Wet Age‐Related Macular Degeneration

Advanced Science, EarlyView.
An integrated approach that combines a DNA nanoflower VEGF degrader with photodynamic therapy is developed for the treatment of wet age‐related macular degeneration, which reduces the risk of VEGF reactivation‐induced CNV recurrence and minimizes the systemic side effects associated with photodynamic therapy.
Mengxuan Li, Yan Yue, Sijin Wu, Xinyu He, Jiayi Song, Shuwen Ma, Haokun Zhang, Chenyu Xu, Song Chen, Yanming Huang, Songbo Xie, Hua Yan   +11 more
wiley   +1 more source

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration

Cost Effectiveness and Resource Allocation, 2008
Background Intravitreal ranibizumab prevents vision loss and improves visual acuity in patients with neovascular age-related macular degeneration, but it is expensive, and efficacy beyond 2 years is uncertain.
Matthews Jane P, Hurley Susan F, Guymer Robyn H   +2 more
doaj   +1 more source

Antibody‐Empowered Nanomedicine for Precise Biomedical Applications

Advanced Science, EarlyView.
This review explores strategies for functionalizing nanoparticles with antibodies to construct antibody‐empowered nanomedicine. It discusses the classification of these nanomedicines based on antibody structure, with a specific focus on their biomedical applications in diagnostics, bioimaging, and therapeutics for various diseases.
Chen Chen, Xinglin Chen, Zhenhao Gao, Meng Sun, Yaozong Yu, Fang Lv, Qiujun Wang, Jinfeng Zhang   +7 more
wiley   +1 more source

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab

Indian Journal of Ophthalmology, 2015
Background: To investigate visual and anatomical outcomes in eyes with exudative age-related macular degeneration treated with intravitreal aflibercept following prior treatment with intravitreal ranibizumab.
Daniel Sanju Narayan, James Muecke
doaj   +1 more source

Nanostructured drug delivery systems for posterior segment eye diseases: Strategies to defy ocular barriers

BMEMat, EarlyView.
Efficient drug delivery to the posterior segment of the eye has long been a challenging issue due to the complex ocular barriers. The review focuses on the promise held by nanoplatforms for barrier penetration and the key mechanisms involved, also highlighting their advantages in achieving efficient drug delivery and superior treatment of PSEDs ...
Yifan Shen, Ying Yao, Yan Zhang, Xinyu Shi, Ling Bai, Yang Zhong, Yan Zhang, Kun Zhang   +7 more
wiley   +1 more source

Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model

International Journal of Ophthalmology, 2013
AIM:To compare the efficacies of subconjunctival bevacizumab, ranibizumab, and pegaptanib sodium injections for the inhibition of corneal neovascularization in an experimental rat model.METHODS:Sixteen corneas of 16 rats were chemically cauterized and ...
Cem Küçükerdönmez, Veysi Öner, Ebru Eren Akar, Yonca Aydın Akova   +3 more
doaj   +1 more source

Image analysis method for measurement and prediction of intra‐matrix IgG diffusion

Biotechnology Progress, EarlyView.
Experimental and image analysis workflow for b‐IgG diffusion in hyaluronic acid (HA) matrix. Abstract Measurement and imaging of intra‐matrix protein therapeutics diffusion is important due to the emergence of injectable biologics currently in various stages of research and clinical testing.
Riya Debbarma, Antonio C. F. dos Santos, Michael Ladisch   +2 more
wiley   +1 more source

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

Clinical Pharmacology &Therapeutics, EarlyView.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono, Martin K. H. Ho, Joanna Yang, Tonya Campbell, William Wynne, Dana Shearer, Lene Andersen, Eric Majer, Shaleesa Ledlie, Mina Tadrous, Tara Gomes   +10 more
wiley   +1 more source

Cost-effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration and its Subtypes from the Societal and Patient Perspectives in Japan

Ophthalmology and Therapy
Introduction This study evaluated the cost-effectiveness of anti-vascular endothelial growth factor (VEGF) therapies for subtypes of neovascular age-related macular degeneration (nAMD) from the societal perspective, and for any nAMD from the patient ...
Yasuo Yanagi, Kanji Takahashi, Tomohiro Iida, Fumi Gomi, Hiroshi Onishi, Junko Morii, Taiji Sakamoto   +6 more
doaj   +1 more source